

# Renato Bassan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1539811/publications.pdf>

Version: 2024-02-01

46  
papers

3,966  
citations

304743

22  
h-index

233421

45  
g-index

46  
all docs

46  
docs citations

46  
times ranked

5255  
citing authors

#	ARTICLE	IF	CITATIONS
1	Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2017, 376, 836-847.	27.0	1,443
2	Modern Therapy of Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 532-543.	1.6	425
3	Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). <i>Blood</i> , 2009, 113, 4153-4162.	1.4	387
4	Dasatinib+Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. <i>New England Journal of Medicine</i> , 2020, 383, 1613-1623.	27.0	279
5	Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. <i>Blood</i> , 2011, 118, 6153-6163.	1.4	227
6	International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. <i>Haematologica</i> , 2016, 101, 1524-1533.	3.5	154
7	DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014073.	1.3	132
8	Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges. <i>Journal of Hematology and Oncology</i> , 2019, 12, 39.	17.0	81
9	Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome+Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1983-1987.	2.0	77
10	A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2019, 104, 2028-2039.	3.5	68
11	New Approaches to the Management of Adult Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 3504-3519.	1.6	67
12	Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma. <i>Haematologica</i> , 2011, 96, 238-244.	3.5	57
13	Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913. <i>Haematologica</i> , 2021, 106, 1559-1568.	3.5	49
14	Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. <i>Hematology</i> , 2019, 24, 337-348.	1.5	48
15	High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program. <i>Haematologica</i> , 2013, 98, 1718-1725.	3.5	40
16	Current and future management of Ph/BCR-ABL positive ALL. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 723-740.	2.4	40
17	Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma. <i>Annals of Hematology</i> , 2012, 91, 73-82.	1.8	36
18	Mutations of TP53 gene in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival. <i>Haematologica</i> , 2016, 101, e245-e248.	3.5	29

#	ARTICLE	IF	CITATIONS
19	Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18â€“65 years: NILG ALL 10/07. <i>Blood Cancer Journal</i> , 2020, 10, 119.	6.2	29
20	Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, 786-793.	3.5	27
21	CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease. <i>Haematologica</i> , 2012, 97, 568-571.	3.5	25
22	Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML. <i>Blood Advances</i> , 2019, 3, 1103-1117.	5.2	23
23	Practical guidance for the management of acute lymphoblastic leukemia in the adolescent and young adult population. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072090353.	2.5	23
24	Minimal Residual Disease Monitoring in Adult ALL to Determine Therapy. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 86-95.	2.3	22
25	Final Results of Northern Italy Leukemia Group (NILG) Trial 10/07 Combining Pediatric-Type Therapy with Minimal Residual Disease Study and Risk-Oriented Hematopoietic Cell Transplantation in Adult Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2016, 128, 176-176.	1.4	21
26	Minimal Residual Disease Assessment and Risk-based Therapy in Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S2-S9.	0.4	20
27	Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCRâ€“ABL rearrangements in B-precursor adult acute lymphoblastic leukemia. <i>The Hematology Journal</i> , 2000, 1, 226-234.	1.4	16
28	Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06. <i>Haematologica</i> , 2021, 106, 2578-2587.	3.5	15
29	Lymphoblastic Lymphoma: a Concise Review. <i>Current Oncology Reports</i> , 2022, 24, 1-12.	4.0	13
30	Capture-Based Next-Generation Sequencing Improves the Identification of Immunoglobulin/T-Cell Receptor Clonal Markers and Gene Mutations in Adult Acute Lymphoblastic Leukemia Patients Lacking Molecular Probes. <i>Cancers</i> , 2020, 12, 1505.	3.7	11
31	Immunotherapy approaches to treat adult acute lymphoblastic leukemia. <i>Expert Review of Hematology</i> , 2016, 9, 563-577.	2.2	10
32	Prolonged administration of all-trans retinoic acid in combination with intensive chemotherapy and G-CSF for adult acute myelogenous leukemia: single-centre pilot study in different risk groups. <i>The Hematology Journal</i> , 2002, 3, 193-200.	1.4	10
33	Using Minimal Residual Disease to Improve Treatment Response Definitions and Hematopoietic Cell Transplantation Strategy in Acute Leukemia. <i>Journal of Clinical Oncology</i> , 2016, 34, 300-302.	1.6	9
34	Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial. <i>Blood Advances</i> , 2020, 4, 301-311.	5.2	8
35	Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease. <i>Cancers</i> , 2019, 11, 1417.	3.7	7
36	Phase I trial with escalating doses of idarubicin and multidrug resistance reversal by short-course cyclosporin A, sequential high-dose cytosine arabinoside, and granulocyte colony-stimulating factor for adult patients with refractory acute leukemia. <i>Haematologica</i> , 2002, 87, 257-63.	3.5	7

#	ARTICLE	IF	CITATIONS
37	Digital Droplet PCR Is a Reliable Tool to Improve Minimal Residual Disease Stratification in Adult Philadelphia-Negative Acute Lymphoblastic Leukemia. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 893-900.	2.8	7
38	High Throughput Molecular Characterization of Normal Karyotype Acute Myeloid Leukemia in the Context of the Prospective Trial 02/06 of the Northern Italy Leukemia Group (NILG). <i>Cancers</i> , 2020, 12, 2242.	3.7	5
39	MRD-Based Therapeutic Decisions in Genetically Defined Subsets of Adolescents and Young Adult Philadelphia-Negative ALL. <i>Cancers</i> , 2021, 13, 2108.	3.7	5
40	Myeloblastic therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia – very long follow-up. <i>British Journal of Haematology</i> , 2014, 167, 724-726.	2.5	4
41	Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocol. <i>Leukemia and Lymphoma</i> , 2019, 60, 3482-3492.	1.3	3
42	Prognostic impact of <i>KMT2A</i> – <i>AFF1</i> positivity in 926 <i>BCR</i> – <i>ABL1</i> –negative B–lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996. <i>American Journal of Hematology</i> , 2021, 96, E334-E338.	4.1	3
43	Immature Immunoglobulin Gene Rearrangements Are Recurrent in B Precursor Adult Acute Lymphoblastic Leukemia Carrying TP53 Molecular Alterations. <i>Genes</i> , 2020, 11, 960.	2.4	2
44	National Italian Delphi panel consensus: which measures are indicated to minimize pegylated-asparaginase associated toxicity during treatment of adult acute lymphoblastic leukemia?. <i>BMC Cancer</i> , 2020, 20, 956.	2.6	1
45	Early peripheral blast cell clearance predicts minimal residual disease status and refines disease prognosis in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1304-1313.	4.1	1
46	Selective liver toxicity and therapeutic progress in acute lymphoblastic leukaemia. <i>Lancet Haematology</i> , 2017, 4, e346-e347.	4.6	0